Case Report: Effectiveness of Targeted Treatment in a Patient With Pancreatic Cancer Harboring PALB2 Germline Mutation and KRAS Somatic Mutation

Wei Wu¹, Yu Liu¹, Yuzhi Jin¹, Lulu Liu¹, Yixuan Guo¹, Mian Xu², Qing Hao², Dazhi Li³, Weijia Fang¹, Aibin Zhang* and Peng Zhao*¹

¹ Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University & Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang, China
² OrigilMed, Shanghai, China
³ Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

Pancreatic cancer is one of the most leading causes of cancer death worldwide. The rapid development of next-generation sequencing (NGS) and precision medicine promote us to seek potential targets for the treatment of pancreatic cancer. Here, we report a female pancreatic cancer patient who underwent radical surgical excision after neoadjuvant chemotherapy. After the surgery, the patient underwent gemcitabine + S-1 therapy, capecitabine + albumin paclitaxel therapy and irinotecan therapy successively, however, MRI review revealed tumor progression. The surgical tissue sample was subjected to next-generation sequencing (NGS), and PALB2 germline mutation and KRAS somatic mutation were identified. The patient then received olaparib (a PARP inhibitor) + irinotecan and the disease stabilized for one year. Due to the increased CA19-9, treatment of the patient with a combination of trametinib (a MEK inhibitor) and hydroxychloroquine resulted in stable disease (SD) with a significant decrease of CA19-9.

This case demonstrated that the NGS may be a reliable method for finding potential therapeutic targets for pancreatic cancer.

Keywords: pancreatic cancer, PALB2 germline mutation, KRAS somatic mutation, targeted therapy, case report

INTRODUCTION

Pancreatic cancer is one of the most deadly malignant tumors in the world (1). So far, surgical resection is still the primary treatment strategy for pancreatic cancer. However, most patients lose the opportunity to undergo radical surgery due to late-stage diagnosis (2). The clinical outcomes of pancreatic cancer remain poor due to limited effective treatments and a high rate of metastasis and recurrence (3). Genetic and epigenetic aberrations related to abnormal activation of tumor driver genes are often found in pancreatic cancer (4). Therefore, targeted therapy may be an important approach to improve the overall survival of pancreatic cancer patients.

Partner and localizer BRCA2 (PALB2) is an important DNA repair gene and plays an essential role in homologous recombination. It links BRCA1 and BRCA2 (5), enabling recombination repair and checkpoint functions in maintaining genomic integrity (6). In addition, it also participates in double-stranded break repair during DNA damage response (7). PALB2 gene mutation mainly...
includes non-sense mutations, frameshift mutations and loss-of-function mutations (8), and PALB2 is identified as a susceptibility gene of pancreatic cancer (9), familial breast cancer (10) and ovarian cancer (11).

The rat sarcoma virus (RAS) family includes more than 150 small monomeric proteins with GTPase activity. Kirsten rat sarcoma viral oncogene homolog (KRAS) belongs to the RAS family, and mutations in KRAS will affect RAS-mediated GTP hydrolysis, leading to the continuous activation of RAS and thereby promoting the malignant transformation of cells (12). KRAS gene activation mutations and amplification are very common in a variety of malignant diseases, such as colon cancer, lung cancer, thyroid cancer and pancreatic cancer (13). It is generally considered that KRAS gene mutation is a poor prognostic factor for a variety of cancers, including pancreatic cancer (14). The cBioPortal database (2020) shows that the frequency of KRAS gene mutations in pancreatic adenocarcinoma is about 85.9–94.9%.

Given the limited data on targeted medication for PALB2 germline mutations and KRAS gene mutation in pancreatic cancer, we herein report a case of a pancreatic cancer patient with PALB2 germline mutation and KRAS mutation, and this patient responses well to targeted therapy.

**CASE PRESENTATION**

The patient, female, 56 years old, was in good health and had no history of any chronic diseases. The patient attended our hospital in October 2016 due to pain in the left lower back and pain and discomfort under the xiphoid. Computed tomography (CT) scan showed space-occupying of the pancreatic tail, invading the abdominal aorta. Endoscopic ultrasonography-guided biopsy of the pancreatic tail was performed and the pathology revealed adenocarcinoma. After multiple disciplinary team (MDT) discussion, the patient was diagnosed with locally advanced pancreatic cancer, and neoadjuvant therapy is recommended first. From October 2016 to July 2017, the patient received GS chemotherapy (a total of 10 courses): Gemcitabine 1600 mg D1, D8 + S-1 60 mg Bid D1-14, Q3W. A restaging CT scan in January 2017 indicated the unavailableness of radical resection. Hence, during GS chemotherapy, 25 rounds of radiotherapy started in January 2017. Magnetic resonance (MR) in July 2017 showed a mass in the pancreatic body with enlarged lymph nodes around the pancreas and retroperitoneum, accompanied by splenic arteriovenous invasion and multiple collateral circulations. Efficacy evaluation was partial response (PR) at that time. Pancreatectomy and splenectomy were performed in our hospital on July 25, 2017, and the pathology of the surgical tissue showed moderate-poorly differentiated adenocarcinoma. A surgical tissue sample was obtained for next-generation sequencing (NGS) using a panel of 450 cancer-related genes (OrigiMed, Shanghai, China) on July 25, 2017. Ultimately, PALB2 (D1168Efs*22) germline mutation and KRAS (G12R) somatic mutation were detected.

After the surgery, from September 2017 to November 2017, the patient was continued to receive GS chemotherapy and radiotherapy. However, on November 17, 2017, restaging MR displayed two abnormal lesions in the left liver, which were considered as liver metastases. Radiofrequency ablation was manipulated and capecitabine 1250 mg bid D1-14 + albumin paclitaxel 200 mg D1, D8, Q3W were given for 6 cycles as chemotherapy from December 2017 to May 2018. Nevertheless, the level of CA19-9 increased dramatically from August 2018 to September 2018, and restaging MR showed anterior abdominal wall mass and retroperitoneal mass, indicating tumor metastasis. Efficacy evaluation was progressive disease (PD).

The patient received irinotecan 250 mg Q3W as chemotherapy for 6 cycles from September 2018 to January 2019. During this period, due to the increase of CA19-9 level (Figure 1), Olaparib combined with irinotecan was used for treatment from October 2018, and the disease stabilized until November 2019 (Figure 2). Due to the increase of CA19-9 (Figure 1), the patient transferred to SOX chemotherapy (oxaliplatin injection 130 mg D1 + S-1 60 mg twice a day, D1–7, Q2W) for 5 cycles from 2019-11 to 2020-1. However, the volume of the anterior abdominal wall mass and retroperitoneal mass increased, indicating disease progression.

In December 2019, the patient began receiving trametinib (2 mg, daily) + hydroxychloroquine (200 mg, twice a day). Nevertheless, the patient's level of CA 19-9 (Figure 1) continued to increase during the first month of treatment. The hydroxychloroquine was escalated to 800 mg daily (400 mg, twice a day) and the trametinib dose was unchanged. During the three months of the treatment, she experienced grade 2 neutropenia and grade 1 fatigue. The CA19-9 level (Figure 1) decreased significantly, and MRI (Figure 3) indicated a 6% reduction in tumor burden by RECIST 1.1 criteria, achieving stable disease (SD).

For the further guidance of next treatment, the blood sample was used for NGS in May 2020, and the results still showed PALB2 (D1168Efs*22) germline mutation and KRAS (G12R) somatic mutation. Unfortunately, the patient's condition worsened suddenly by a severe gastrointestinal hemorrhage leading to death in July 2020.

**DISCUSSION**

Pancreatic cancer is a lethal tumor with limited treatment regimens. The adoption of molecular-guided precision medicine with targeted therapy has revealed immense value in improving the treatment effect and prognosis of patients with pancreatic cancer (15, 16). We present a successful case of targeted therapy in the treatment of locally advanced pancreatic cancer after multiple-line therapies. PALB2 (D1168Efs*22) germline mutation and KRAS (G12R) somatic mutation were detected in the patient through NGS.

**PALB2 Mutation**

PALB2 encodes a chaperone and localization protein of BRCA2 which stabilizes BRCA2 localization and promotes BRCA2 accumulation in the nucleus. PALB2 preferentially recognizes the D-loop structure of DNA, directly interacts with the recombinant RAD51, and activates the DNA insertion which is crucial for the homologous recombination repair process (17).
PALB2 has been identified as one of the major known susceptibility genes for pancreatic cancer (9). The germline mutation of PALB2, a significant gene in regulating homologous recombination and mediating DNA damage response, could cause DNA replication and damage response defects (18). In a study analyzing data from 524 families with germline PALB2

pathogenic variants, an increased risk of pancreatic cancer was observed in PALB2 pathogenic variants carriers (19). Another study has verified that the germline PALB2 mutation was associated with an increased risk of developing pancreatic ductal adenocarcinoma (PDAC) in patients with intraductal papillary mucinous neoplasms (20).

The NCCN guidelines (V1.2020) recommend that patients with metastatic or locally advanced pancreatic cancer who carry deleterious germline BRCA1/2 or PALB2 variants should be treated with platinum-containing chemotherapy for first-line treatment, and NCCN guidelines also recommend considering olaparib as maintenance treatment for patients who have a deleterious germline BRCA1/2 based on the results of the phase 3 POLO trial (21). In a single-center retrospective study, 11 patients with metastatic pancreatic cancer (6 patients with BRCA2 mutations, 2 patients with ATM mutations, 1 patient with BRCA1 mutations, 1 patient with PALB2 mutations, and 1 patient with C11orf30 mutations) who received at least first-line system therapy were treated with olaparib, and the median duration of olaparib treatment was 5 months, ORR was 18%, and the average OS was 12.35 months (22). Preliminary results of a phase II clinical trial (NCT01585805) examining a PARP inhibitor veliparib in the treatment of previously treated pancreatic cancer (carrying BRCA1/2 or PALB2 variants) showed that veliparib was well-tolerated and 4 (25%) patients who received veliparib monotherapy achieved SD for more than 4 months (23).

Our patient received Olaparib combined with irinotecan when the tumor progressed after multiple-line therapies. The patient responses well to this combined therapy; stable disease was sustained from October 2018 to November 2019.

**KRAS Mutation**

RAS are common oncogenes in human tumors. Genes such as NRAS, KRAS, and HRAS are frequently mutated. KRAS mutations mainly occur in amino acid codons 12, 13, and 61, inhibiting the GTP-mediated hydrolysis process, leading to the continuous activation of RAS, and thereby promoting the malignant transformation of cells (24).

KRAS mutation is the initiating genetic event for PDAC. KRAS mutations are identified in 85% of American pancreatic cancer patients, and the vast majority of mutations occur at codon 12. Double KRAS mutations often coexist in the same pancreatic cancer lesion, which may further promote tumorigenesis (25). It is generally believed that KRAS gene mutation is a poor prognostic factor for pancreatic cancer (24).

There is no FDA approved anti-tumor drug targeting KRAS gene for now, and MEK inhibitors have shown certain clinical effects on the treatment of cancers with KRAS mutation. In a phase II clinical trial (NCT01222689) enrolled 46 patients with advanced pancreatic cancer, the patients received a combination treatment of Selumetinib (MEK inhibitor) and erlotinib (EGFR TKI), and 19 patients (41%) had stable disease, of which 12 patients kept stable for more than 12 weeks, and 12 patients showed lesion shrinkage, with a median progression-free survival of 1.9 months and a median overall survival of 7.3 months (26). In a phase I clinical trial (NCT00687622), 22 patients with KRAS mutation-positive non-small cell lung cancer were treated with trametinib, of which 8 patients showed tumor shrinkage (6–52%); 2 non-small cell lung cancer patients (1 case of KRAS mutation, 1 case of KRAS/BRAF double mutation) and 2 cases of pancreatic cancer (1 case of KRAS mutation, 1 case of unknown) showed partial remission (27). It has been verified that inhibition of KRAS→ RAF→ MEK→ ERK signaling elicits autophagy, a process of cellular recycling that protects PDA cells from the cytotoxic effects of KRAS pathway inhibition. Hence, MEK inhibitors in combination with hydroxychloroquine, a 4-aminoquinolone which shows effects on inhibiting autophagy, may show better cancer suppressing effects. In a 68-year-old patient with metastatic pancreatic cancer, after receiving trametinib plus hydroxychloroquine treatment, the tumor marker level was reduced by 50% and the lesion was significantly reduced (28).

This patient received combination therapy of trametinib and hydroxychloroquine since January 2020. The MRI (Figure 3) indicated SD in April 2020 and a significant decrease in the CA19-9 level (Figure 1) was observed in May 2020.

Recently, an increasing number of predictive signatures/genes were identified by molecular studies for a given therapy. In early-stage PDAC patients, SMAD4 aberrations were identified as a negative prognostic marker in the gemcitabine arm, and SMAD4 alteration status was associated with erlotinib effectiveness (29). The genome-wide RNA-based gemcitabine sensitivity stratification could predict the clinical benefit of adjuvant gemcitabine in PDAC patients (30). These studies demonstrated the great importance of NGS-based sequencing technology in guiding precision therapy in PDAC. Unfortunately, the patient died in July 2020 because of a severe gastrointestinal hemorrhage. The overall survival of this locally advanced pancreatic cancer patient was ∼45 months, with a progression-free survival of ∼18 months for NGS-based targeted therapy after multiple-line therapies.

**CONCLUSION**

We report a locally advanced pancreatic cancer patient who harbors PALB2 germline mutation and KRAS somatic mutation receiving targeted therapy. Fairly satisfactory efficacy of NGS-targeted therapy after multiple-line therapies was observed in this patient. This case demonstrated that targeted therapy based on the potential therapeutic targets detected by the NGS may be an important approach to improve the survival of pancreatic cancer patients.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.
ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

WW, YL, LL, YG, WF, PZ, and AZ collected the clinical information, diagnostic information, therapeutic information, and images of the patients. MX and QH provided the NGS result and some advisable information for the result. WW wrote and submitted the manuscript. YL, YJ, LL, DL, PZ, and AZ revised the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. (2020) 70:7–30. doi: 10.3322/caac.21590
2. Chu LC, Goggins MG, Fischman EK. Diagnosis and detection of pancreatic cancer. Cancer J. (2017) 23:333–42. doi: 10.1097/PPO.0000000000000290
3. Klopman S, de Rooij T, Korteweg JJ, van Dieren S, van Lienden KP, van Gulik TM, et al. Systematic review of outcomes after distal pancreatectomy with coeliac axis resection for locally advanced pancreatic cancer. Br J Surg. (2016) 103:941–9. doi: 10.1002/bjs.10148
4. Jakel C, Bergmann F, Toth R, Assenov Y, van der Duin D, Strobel O, et al. Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. Nat Commun. (2017) 8:1323. doi: 10.1038/s41467-017-01118-x
5. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol. (2009) 19:524–9. doi: 10.1016/j.cub.2009.01.008
6. Sy SM, Huen MS, Zhu Y, Chen J. PALB2 regulates recombinational repair through chromatin association and oligomerization. J Biol Chem. (2009) 284:18302–10. doi: 10.1074/jbc.M109.016717
7. Xia B, Sheng Q, Nakanishi K, Ohashi A, Wu J, Christ N, et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell. (2006) 22:719–29. doi: 10.1016/j.molcel.2005.05.022
8. Pauty J, Rodrigue A, Couturier A, Buisson R, Masson JY. Exploring the roles of PALB2 at thecrossroads of DNA repair and cancer. Biochem J. (2014) 463:331–42. doi: 10.1042/BJ20140208
9. Jones S, Hruban RH, Kimmathy M, Borges M, Zhang X, Parsons DW, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. (2009) 324:217. doi: 10.1126/science.1171202
10. Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. (2014) 371:497–506. doi: 10.1056/NEJMoa1400382
11. Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, Niwinska A, et al. A novel germline PALB2 deletion in polish breast and ovarian cancer patients. BMC Med Genet. (2010) 11:20. doi: 10.1186/1471-2350-11-20
12. Birkeland E, Wik E, Mjos S, Hoivik EA, Trovik J, Werner HM, et al. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. Br J Cancer. (2012) 107:997–2004. doi: 10.1038/bjc.2012.477
13. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol. (2008) 9:517–31. doi: 10.1038/nrm2438
14. Kim ST, Lim DH, Jang KT, Lim T, Lee J, Choi YL, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther. (2011) 10:1993–9. doi: 10.1158/1535-7163.MCT-11-0269
15. Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. (2020) 21:508–18. doi: 10.1016/S1470-2045(20)30074-7
16. Aguirre AJ, Nowak JA, Camarda ND, Moftitt RA, Ghazani AA, Hazar-Rethinam M, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer discovery. (2018) 8:1096–111. doi: 10.1158/2159-8290.CD-18-0275
17. Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. (2010) 17:1247–54. doi: 10.1038/nsmb.1915
18. Nikkila J, Parpys AC, Pylkas K, Bose M, Hoo Y, Borgmann K, et al. Heterozygous mutations in PALB2 cause DNA replication and damage response defects. Nat Commun. (2013) 4:2578. doi: 10.1038/ncomms3578
19. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. (2020) 38:674–85. doi: 10.1200/JCO.19.01907
20. Skaro M, Nanda N, Gauthier C, Felsenstein M, Jiang Z, Qiu M, et al. Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms. Gastroenterology. (2019) 156:1905–13. doi: 10.1033/j.gastro.2019.01.254
21. Golan T, Himmel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. (2019) 381:317–27. doi: 10.1056/NEJMoa1903387
22. Borazanci EH, Guarnieri C, Haag S, Korn RL, Snyder CE, Hendrickson K, et al. Retrospective analysis of patients using olaparib (O) in pancreatic cancer (PC). J Clin Oncol. (2018) 36:389. doi: 10.1200/JCO.2018.36.4_sup.389
23. Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreatic ductal adenocarcinoma. Eur J Cancer. (2018) 89:19–26. doi: 10.1016/j.ejca.2017.11.004
24. Guerrero S, Casanova I, Farre L, Mazo A, Capella G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. (2000) 60:6750–6.
25. Visani M, de Biase D, Baccarini P, Fabbri C, Polifemo AM, Zanini N, et al. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells. Int J Surg Pathol. (2013) 21:546–52. doi: 10.1177/1066896912475073
26. Ko AH, Bekaii-Saab T, Van Ziffle J, Mirzoeva OM, Joseph NM, Talasz A, et al. A multicenter, open-label phase ii clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory...

FUNDING

This study was sponsored by National Natural Science Foundation of China (82074208 and 81472346), Zhejiang Provincial Natural Science Foundation (LY20H160033) and A Project Supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202045581).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2021.746637/full#supplementary-material
advanced pancreatic adenocarcinoma. Clin Cancer Res. (2016) 22:61–8. doi: 10.1158/1078-0432.CCR-15-0979

27. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. (2012) 13:773–81. doi: 10.1016/S1470-2045(12)70270-X

28. Kinsey CG, Camolootto SA, Boespflug AM, Guilling KP, Foth M, Truong A, et al. Protective autophagy elicited by RAF–MEK–ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. (2019) 25:620–7. doi: 10.1038/s41591-019-0367-9

29. Hoyer K, Hablesreiter R, Inoue Y, Yoshida K, Briest F, Christen F, et al. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: results from the CONKO-005 trial. EBiomedicine. (2021) 66:103327. doi: 10.1016/j.ebiom.2021.103327

30. Nicolle R, Gayet O, Guerci P, Vanbrugghe C, Roques J, Bigonnet M, et al. A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. Ann Oncol. (2021) 32:250–60. doi: 10.1016/j.annonc.2020.10.601

Conflict of Interest: MX and QH were employed by the company OrigiMed.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wu, Liu, Liu, Guo, Xu, Hao, Li, Fang, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.